Welcome to our dedicated page for Rain Enhancement news (Ticker: RAIN), a resource for investors and traders seeking the latest updates and insights on Rain Enhancement stock.
Rain Enhancement Technologies Holdco, Inc. develops, manufactures, and commercializes ionization precipitation generation technology for rainfall and snowpack enhancement. Its updates center on the Weather Enhancement Technology Array (WETA), U.S. installations, weather-modification permits, independent analyses of agricultural water benefits, and reported precipitation results in mountain and arid environments.
The company also reports research into adjacent atmospheric applications, including fog mitigation and air pollution or smog mitigation. Governance updates and commercialization milestones appear alongside technical disclosures about its chemical-free, solar-powered ionization approach.
Rain Therapeutics has announced the commencement of a Phase 3 trial (MANTRA) evaluating milademetan (RAIN-32) in patients with de-differentiated liposarcoma (DD LPS). This pivotal study, which aims to showcase the efficacy of milademetan against the standard treatment, trabectedin, is set to involve approximately 160 patients. Notably, previous studies show that patients have experienced long-term therapy for over 4 years with milademetan, indicating a favorable safety profile. The trial focuses on progression-free survival, aiming to fulfill a significant unmet medical need.
Rain Therapeutics Inc. has announced a partnership with Tempus to enhance its Phase 2 clinical trial for RAIN-32, targeting MDM2-amplified tumors. The trial is set to commence in the second half of 2021, focusing on utilizing Tempus' genomic analysis platform for patient matching and tumor profiling. RAIN-32, an oral MDM2 inhibitor, demonstrated significant anti-tumor activity in previous trials. The company plans to initiate a pivotal Phase 3 trial for liposarcoma and a Phase 2 tumor-agnostic basket trial later this year. RAIN-32 has already received FDA Orphan Drug Designation.
Rain Therapeutics has partnered with Caris Life Sciences to enhance patient referrals for its upcoming Phase 2 clinical trial of RAIN-32, an oral MDM2 inhibitor targeting cancers with MDM2 amplification. Set to begin in H2 2021, this novel trial will leverage Caris' molecular profiling technology to identify eligible patients across various solid tumors. Additionally, RAIN-32 has shown promising antitumor activity in prior studies, leading to plans for a pivotal Phase 3 trial in liposarcoma. The FDA has granted RAIN-32 Orphan Drug Designation, underscoring its potential.
Rain Therapeutics Inc. will be represented by CEO Avanish Vellanki at the Goldman Sachs 42nd Annual Global Healthcare Conference from June 8-11, 2021. He will present a corporate overview and engage in one-on-one investor meetings on June 10 at 5:30 p.m. ET. The presentation will be accessible via a webcast link and on the company's website. A replay will be available for 30 days following the event. Rain focuses on precision oncology, with its lead product RAIN-32 targeting MDM2 in various cancers.
Rain Therapeutics Inc. completed its IPO in April 2021, generating net proceeds of $121.9 million. The company plans to initiate a Phase 3 trial for RAIN-32 in well-differentiated/de-differentiated liposarcoma and an open-label Phase 2 basket trial for MDM2-amplified tumors, both set for 2H 2021. The first quarter results showed a net loss of $6.8 million compared to $2.6 million in Q1 2020, with R&D expenses significantly rising. Rain aims to end 2021 with a projected cash balance of $137 million to $147 million.
Rain Therapeutics has appointed co-founder Dr. Robert Doebele as president and chief scientific officer, enhancing its leadership as it approaches a critical Phase 3 clinical trial for RAIN-32. Dr. Doebele, an expert in precision oncology, will shape the company's strategy and operations. The leadership transition comes as Rain prepares for its Phase 3 trial for liposarcoma patients in late 2021. The company focuses on precision therapies that target oncogenic drivers, notably RAIN-32, an oral MDM2 inhibitor. Rain is positioned for growth following a recent IPO.
Rain Therapeutics Inc. has announced the pricing of its initial public offering (IPO) of 7,352,941 shares at $17.00 per share, aiming for gross proceeds of approximately $125.0 million. The shares are set to trade on the Nasdaq under the ticker symbol RAIN starting April 23, 2021. A 30-day option for underwriters to purchase an additional 1,102,941 shares at the IPO price is also provided. The offering is expected to close on April 27, 2021, subject to standard closing conditions.